ArriVent BioPharma Files 8-K/A Amendment
Ticker: AVBP · Form: 8-K/A · Filed: Jul 9, 2024 · CIK: 1868279
| Field | Detail |
|---|---|
| Company | Arrivent Biopharma, INC. (AVBP) |
| Form Type | 8-K/A |
| Filed Date | Jul 9, 2024 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.0001, $352,500, $45,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, executive-changes, amendment
TL;DR
ArriVent BioPharma amended its 8-K filing, updating info on exec changes and compensation.
AI Summary
ArriVent BioPharma, Inc. filed an amendment (8-K/A) on July 9, 2024, to its report originally dated April 20, 2024. This amendment pertains to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements for certain officers. The filing also includes financial statements and exhibits.
Why It Matters
This amendment provides updated information regarding the company's leadership and executive compensation, which can impact investor confidence and strategic direction.
Risk Assessment
Risk Level: low — The filing is an amendment to a previous report and primarily concerns corporate governance and executive appointments, not a material adverse event.
Key Players & Entities
- ArriVent BioPharma, Inc. (company) — Registrant
- 0001104659-24-078585 (filing_id) — Accession Number
- 20240709 (date) — Filing Date
- 20240420 (date) — Report Date
FAQ
What specific items are being amended in this 8-K/A filing?
This 8-K/A filing amends items related to the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements of certain officers.
What was the original report date for the filing being amended?
The original report date for the filing being amended was April 20, 2024.
When was this amendment (8-K/A) filed with the SEC?
This amendment was filed on July 9, 2024.
What is the Commission File Number for ArriVent BioPharma, Inc.?
The Commission File Number for ArriVent BioPharma, Inc. is 001-41929.
What is the business address of ArriVent BioPharma, Inc.?
The business address of ArriVent BioPharma, Inc. is 18 Campus Boulevard, Suite 100, Newtown Square, PA 19073-3269.
Filing Stats: 1,129 words · 5 min read · ~4 pages · Grade level 10.6 · Accepted 2024-07-09 17:03:37
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share AVBP The Nasdaq
- $352,500 — Date"), with a Grant Date fair value of $352,500 (the "Option"). The Option will vest an
- $45,000 — d to receive an annual cash retainer of $45,000 for her service as a non-employee direc
Filing Documents
- tm2419108-1_8ka.htm (8-K/A) — 32KB
- tm2419108d1_ex99-1.htm (EX-99.1) — 9KB
- tm2419108d1_ex99-1img001.jpg (GRAPHIC) — 3KB
- 0001104659-24-078585.txt ( ) — 226KB
- avbp-20240420.xsd (EX-101.SCH) — 3KB
- avbp-20240420_lab.xml (EX-101.LAB) — 33KB
- avbp-20240420_pre.xml (EX-101.PRE) — 22KB
- tm2419108-1_8ka_htm.xml (XML) — 4KB
02 Departure
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 20, 2024, the Board of Directors (the "Board") of ArriVent BioPharma, Inc. (the "Company") appointed Kristine Peterson to the Board, effective immediately (the "Effective Date"). Ms. Peterson will serve as a Class III Director until the Company's 2027 annual meeting of stockholders and until her successor has been duly elected and qualified, or until her earlier death, resignation, retirement or removal. Ms. Peterson, age 64, most recently served as Chief Executive Officer for Valeritas, Inc. from 2009 to 2016. Prior to joining Valeritas, Ms. Peterson was Company Group Chair of the biotechnology group at Johnson & Johnson from 2006 until 2009, where she was responsible for Commercial, Research & Development, and biologics manufacturing for oncology, immunology and cell therapy, and was Executive Vice President of Pharmaceutical Group Strategic Marketing from 2004 to 2006. Previously, she served as President and Senior Vice President, Commercial Operations for Biovail Corporation. Earlier in her career, Ms. Peterson spent 20 years at Bristol-Myers Squibb Company in a variety of senior roles across multiple disease areas, including running their cardiovascular and metabolics business unit. Ms. Peterson has served on the boards of directors of Enanta Pharmaceuticals since September 2017 and Immunocore Holdings since November 2017. She previously served on the boards of directors for ImmunoGen, Inc., Amarin Corporation plc, EyePoint Pharmaceuticals and Paratek Pharmaceuticals. Additionally, she previously served as a senior advisor to the Healthcare Businesswomen's Association and a Member of the Biotechnology Industry Organization (BIO) Board. Ms. Peterson has a B.S. and an M.B.A. from the University of Illinois at Urbana-Champaign. The Board has affirmatively determined that Ms. Peterson is an indepen
01Financial
Item 9.01Financial (d) Exhibits. Exhibit No. Description 99.1 Press Release dated April 22, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ARRIVENT BIOPHARMA, INC. By: /s/ Winston Kung, MBA Winston Kung, MBA Chief Financial Officer and Treasurer Date: July 9, 2024